Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC)

Bharmal, M., Amin, A., Stapelkamp, C. et al. (5 more authors) (2018) Cost-effectiveness (CE) of avelumab vs standard care (SC) for the treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC). In: Annals of Oncology. 43rd ESMO Congress (ESMO 2018), 19-23 Oct 2018, Munich, Germany. Elsevier , p. 461.

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2018 The Authors.
Dates:
  • Published (online): 27 January 2020
  • Published: 19 October 2018
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 04 Feb 2021 10:45
Last Modified: 04 Feb 2021 10:45
Status: Published
Publisher: Elsevier
Identification Number: https://doi.org/10.1093/annonc/mdy289.047
Related URLs:

Download not available

A full text copy of this item is not currently available from White Rose Research Online

Share / Export

Statistics